- Home
- PDSB vs RNXT Comparison
PDSB vs RNXT Comparison
Compare PDSB & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- RNXT
- Stock Information
- Founded
- PDSB 2005
- RNXT 2012
- Country
- PDSB United States
- RNXT United States
- Employees
- PDSB N/A
- RNXT N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- RNXT Health Care
- Exchange
- PDSB Nasdaq
- RNXT Nasdaq
- Market Cap
- PDSB 44.5M
- RNXT 44.0M
- IPO Year
- PDSB N/A
- RNXT 2021
- Fundamental
- Price
- PDSB $0.94
- RNXT $1.16
- Analyst Decision
- PDSB Strong Buy
- RNXT Strong Buy
- Analyst Count
- PDSB 2
- RNXT 2
- Target Price
- PDSB $10.00
- RNXT $7.50
- AVG Volume (30 Days)
- PDSB 489.6K
- RNXT 604.5K
- Earning Date
- PDSB 11-13-2025
- RNXT 11-12-2025
- Dividend Yield
- PDSB N/A
- RNXT N/A
- EPS Growth
- PDSB N/A
- RNXT N/A
- EPS
- PDSB N/A
- RNXT N/A
- Revenue
- PDSB N/A
- RNXT $662,000.00
- Revenue This Year
- PDSB N/A
- RNXT $2,895.35
- Revenue Next Year
- PDSB N/A
- RNXT $313.04
- P/E Ratio
- PDSB N/A
- RNXT N/A
- Revenue Growth
- PDSB N/A
- RNXT N/A
- 52 Week Low
- PDSB $0.85
- RNXT $0.75
- 52 Week High
- PDSB $3.48
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PDSB 40.57
- RNXT 49.71
- Support Level
- PDSB $0.89
- RNXT $1.12
- Resistance Level
- PDSB $1.03
- RNXT $1.19
- Average True Range (ATR)
- PDSB 0.06
- RNXT 0.09
- MACD
- PDSB 0.00
- RNXT -0.00
- Stochastic Oscillator
- PDSB 31.67
- RNXT 52.00
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.